Specifically, based on its mechanism, “IL-23 is viewed by some as the overarching master cytokine in the psoriasis pathway,” said Fernandez, clinical assistant professor in the Department of ...

Results from a subgroup of the ICONIC-LEAD study show 75% of adolescents with plaque psoriasis achieved completely clear skin ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Good morning, and welcome to Johnson & Johnson's First Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode until the question-and-answer session of the conference. This ...

The IL-23 pathway is already targeted by various injectable antibody-based drugs, including AbbVie's own Skyrizi (risankizumab) – which is FDA-approved for plaque psoriasis, psoriatic arthritis ...

Downstream in the immune cascade, TYK2 inhibitors of the IL-12 and IL-23 pathway involved in psoriasis and Crohn’s disease are gaining momentum, as they avoid impact on haematopoiesis compared ...

I think combination therapy is coming; it’s just a question of which combinations,’ says Arthur Kavanaugh, MD.

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and more frequent adverse events. The study used the Dutch BioCAPTURE ...

Blocking IL-23 may block other proinflammatory cytokines implicated in psoriasis. ORLANDO — Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among ...

One such messenger is interleukin-12 (IL-12). Through meticulous analyses, research teams led by Professor Frank Heppner, Director of the Department of Neuropathology at Charité ...